BridgeBio Pharma to Participate in November Investor Events
PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences:
- Jefferies Health Care Conference, London, UK: November 15th at 9:40 am ET
- Evercore ISI HealthCONx Conference, Virtual: November 30th at 10:05 am ET
To access the live webcast of BridgeBio’s presentations, please visit the “Events” page within the Investors section of the BridgeBio website at https://investor.bridgebiodev.wpengine.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage
biopharmaceutical company founded to discover, create, test and
deliver transformative medicines to treat patients who suffer
from genetic diseases and cancers with clear genetic drivers.
BridgeBio’s pipeline of development programs ranges from early
science to advanced clinical trials. BridgeBio was founded in
2015 and its team of experienced drug discoverers, developers
and innovators are committed to applying advances in genetic
medicine to help patients as quickly as possible. For more
information visit bridgebiodev.wpengine.com and follow us on LinkedIn and Twitter.
BridgeBio Contact:
Vikram Bali
[email protected]
(650)-789-8220